Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CEU
|
|||
| Former ID |
DAP000142
|
|||
| Drug Name |
Flunarizine
|
|||
| Synonyms |
Flufenal; Flunarizin; Flunarizina; Flunarizinum; Fluvert; Issium; Sibelium; Vertix; Zinasen; Apo-flunarizine capsules; Flunarizina [INN-Spanish]; Flunarizine (INN); Flunarizine [INN:BAN]; Flunarizinum [INN-Latin]; Novo-Flunarizine; R-14950; Sibelium (TN); (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine; 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Migraine [ICD-11: 8A80; ICD-10: G43, G43.9; ICD-9: 346] | Approved | [1] | |
| Therapeutic Class |
Anticonvulsants
|
|||
| Company |
Janssen Pharmaceutica
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H26F2N2
|
|||
| Canonical SMILES |
C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
|
|||
| InChI |
1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
|
|||
| InChIKey |
SMANXXCATUTDDT-QPJJXVBHSA-N
|
|||
| CAS Number |
CAS 52468-60-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979238, 9208288, 10525243, 14879384, 26751607, 26751608, 44891609, 46507129, 47216516, 47216517, 47439976, 47515052, 47515053, 47515054, 47515055, 47588728, 47588729, 47736197, 48184716, 49698432, 50011452, 50104264, 50104265, 56365814, 57408889, 80028030, 81093273, 85787717, 85788409, 85788604, 90341204, 92308837, 92309757, 92711460, 96024666, 99300671, 99302189, 103050123, 103096316, 103153578, 103199419, 103928970, 104179181, 110096637, 117509719, 124526360, 124749784, 124883264, 124883265, 124883266
|
|||
| ChEBI ID |
CHEBI:92209
|
|||
| SuperDrug ATC ID |
N07CA03
|
|||
| SuperDrug CAS ID |
cas=052468607
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Flunarizine dihydrochloride (adjusted p-values: 4.68E-03). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012102. | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 3 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 4 | Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. | |||
| REF 5 | Migraine prophylaxis with calcium antagonists: a haemodynamic study using transcranial Doppler ultrasound. Rev Neurol. 2004 Feb 16-29;38(4):316-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.